A place of intravenous immunoglobulins in current clinical practice: Privigen is a novel 10% immunoglobulin

Latysheva T.V.; Latysheva E.A.; Martynova I.A.

doi:https://doi.org/10.17116/terarkh201688482-87

Latysheva T.V.

National Research Center “Institute of Immunology”, Federal Biomedical Agency, Moscow, Russia

Latysheva E.A.

National Research Center “Institute of Immunology”, Federal Biomedical Agency, Moscow, Russia

Martynova I.A.

National Research Center “Institute of Immunology”, Federal Biomedical Agency, Moscow, Russia

A place of intravenous immunoglobulins in current clinical practice: Privigen is a novel 10% immunoglobulin

Authors:

Latysheva T.V., Latysheva E.A., Martynova I.A.

More about the authors

Journal: Therapeutic Archive. 2016;88(4): 82‑87

DOI: 10.17116/terarkh201688482-87

Read: 6020 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Latysheva TV, Latysheva EA, Martynova IA. A place of intravenous immunoglobulins in current clinical practice: Privigen is a novel 10% immunoglobulin. Therapeutic Archive. 2016;88(4):82‑87. (In Russ.)
https://doi.org/10.17116/terarkh201688482-87

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Integrative principles of adaptive medical immunology in the treatment of secondary immunodeficiency: relevance of interdisciplinary interactions. Journal of Adaptive Medical Immunology and Public Health Issues. 2025;(1):6-20

Abstract:

Intravenous immunoglobulins (IVIGs) were initially designed to treat patients with primary immunodeficiencies (PID). Due to the multidirectional effect of IVIGs on the immune system, a range of nosological entities, in which these agents are successfully administered, is steadily expanding. As of now, IVIGs are successfully used in neurology, rheumatology, hematology, and oncology and they are essential drugs for many patients. In spite of the long experience with IVIGs, their mechanism of action remains unclear, numerous investigations for their clinical introduction are being continued. Therefore, there is a growing need to increase the production of the drugs, which gives rise to the emergence of novel medications, which differ in their composition and manufacture technologies, on the pharmacological market. The 10% intravenous immunoglobulin privigen, the safety and efficacy of which has been proven in foreign practice, is a novel drug on the Russian market.

Keywords:

primary immunodeficiency

replacement immunotherapy

intravenous immunoglobulins

immunomodulatory therapy

Authors:

Latysheva T.V.

National Research Center “Institute of Immunology”, Federal Biomedical Agency, Moscow, Russia

Latysheva E.A.

National Research Center “Institute of Immunology”, Federal Biomedical Agency, Moscow, Russia

Martynova I.A.

National Research Center “Institute of Immunology”, Federal Biomedical Agency, Moscow, Russia

Close metadata

References:

Anderson D, Ali K, Blanchette V, Brouwers M, Couban S, Radmoor P, Huebsch L, Hume H, McLeod A, Meyer R, Moltzan C, Nahirniak S, Nantel S, Pineo G, and Rock G. Guidelines on the Use of Intravenous Immune Globulin for Hematologic Conditions. Transfusion Med Rev. 2007;21(2) Suppl 1:S9-S56. doi:10.1016/j.tmrv.2007.01.001.
Kondratenko I, Zaplatnikov A, Bologov A. Intravenous immunoglobulins: the what and when? (Lecture). Detskaya bol'nitsa. 2010;4:56-60. http://www.rdkb.ru/files/file217.pdf
Privigen Product Monograph (In Russ.)
Donyush E. Use of intravenous immunoglobulins in clinical practice Voprosy sovremennoi pediatrii. 2011;2(10):49-63.
Latysheva T. Intravenous immunoglobulin (IVIG) in clinical practice: manual for doctors. Ekon-Inform; 2009.
Rayner X Berger, Stefaniya M, Bode-Berger, Yurgen Ts, Frolih. Inravenous immunoglobulins. Medizinische klinic. 1995;9:520-526. (In Russ.)
Allergology and immunology. National guideline. Brief edition. Khaitov R, Il'ina N. Moscow: GEOTAR-media; 2013. (In Russ.)
Kaveri SV, Maddur MS, Hegde P, Lacroix-Desmazes S, Bayry J. Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy. Clin Exp Immunol. 2011;164 Suppl 2:2-5. doi:10.1111/j.1365-2249.2011.04387.x.
Latysheva E, Latysheva T. Intravenous immunoglobulin application in clinical practice. Pediatricheskaya farmakologiya. 2013;1(10):26-30. doi:10.15690/pf.v10i1.586.
Clinical Guidelines for immunoglobulin use. Second edition update. Department of Health. July 2011 http://www.ivig.nhs.uk/documents/dh_129666.pdf
AAAAI Position Paper: Use of IGIV — January 2005 http://www.aaaai.org/Aaaai/media/MediaLibrary/PDF%20Documents/Practice%20and%20Parameters/IGIV-2005.pdf
Compagno N, Malipiero G, Cinetto F, Agostini C. Immunoglobulin Replacement Therapy in Secondary Hypogammaglobulinemia. Front Immunol. 2014;5:626. doi:10.3389/fimmu.2014.00626.
Elovaara А, Apostolski S, van Doorn P, Gilhus NE, Hietaharju A, Honkaniemi J, van Schaik IN, Scolding N, Soelberg Sørensen P, Udd B. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol. 2008;15:893-908. doi:10.1111/j.1468-1331.2008.02246.x.
Mulhearn B, Bruce IN. Indications for IVIG in Rheumatic Diseases. Rheumatology. 2015;54(3):383-391. doi:10.1093/rheumatology/keu429.
Spycher MO, Kronthaler U, Dickneite G. Investigation of potential neurological effects of stabilizers used in immunoglobulin products for intravenous use: comparison of L-proline and glycine. Presented at the American College of Allergy, Asthma and Immunology, Dallas, Texas, USA, November 8ollege of Allergy, Asthma
Centers for Disease Control and Prevention (CDC). Renal insufficiency and failure associated with immune globulin intravenous therapy— United States, 1985—1998. Morb Mortal Weekly Rep. 1999;48(24):518-518i.
Spycher MO, Bolli R, Hodler G, Gennari K, Hubsch A, Spath P, Schnorf J. Well-tolerated liquid intravenous immunoglobulin G preparations (IVIGs) have a low immunoglobulin G dimer (IgG-dimer) content. J Autoimmun. 1999;96(Suppl. 1):96.
Privigen: Prescribing Information. http://labeling.cslbehring.com/PI/US/Privigen/EN/Privigen-Prescribing-Information.pdf. (In Russ.)
Stein MR, Nelson RP, Church JA, Wasserman RL, Borte M, Vermylen C, Bichler J, for the IgPro10 in PID study group. Safety and efficacy of Privigen, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies. J Clin Imunol. 2009;29(1):137-144. doi:10.1007/s10875-008-9231-2.
Church JA, Leibl H, Stein MR, Melamed IR, Rubinstein A, Schneider LC, Wasserman RL, Pavlova BG, Birthistle K, Mancini M, Fritsch S, Patrone L, Moore-Perry K, Ehrlich HJ; US-PID-IGIV 10% Study Group 10. Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiency. J Clin Immunol. 2006;26(4):388-395. doi:10.1007/s10875-006-9025-3.
Hoffmann R, Lotichius P, Pfruender D. Efficacy and tolerability of polyvalent intravenous immunoglobulin (IVIG) PrivigenR — a multicenter noninterventional study. J Allergy Clin Immunol. 2010;125(2):AB141. doi:10.1016/j.jaci.2009.12.554.
Robak T, Salama A, Kovaleva L, Vyhovska YI, Davies S, Mazzucconi MG, Zenker O, Kiessling P, for the International PrivigenR in ITP Study Group. Efficacy and safety of PrivigenR, a novel liquid intravenous immunoglobulin formulation, in adolescent and adult patients with chronic immune thrombocytopenic purpura. Hematology. 2009;14(4):227-236. doi:10.1179/102453309x439773.
Leger J, De Bleecker J, Sommer C, Robberecht W, Saarela M, Kamienowski J, Stelmasiak Z, Mielke O, Tackenberg B, Shebl A, Bauhofer A, Zenker O, Merkies I. Efficacy and safety of Privigen in patients with inflammatory demyelinating polyneuropathy: a prospective, single-arm, open-label Phase III study (the PRIMA study). J Peripheral Nervous System. 2013;18(2):130-140. doi:10.1111/jns5.12017.